Pacific Biosciences of California, Inc. Revenue from Contract with Customer, Including Assessed Tax
Pacific Biosciences of California, Inc. (PACB) reported Revenue from Contract with Customer, Including Assessed Tax of $39.01 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2026-08-06
- Pacific Biosciences of California, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2026-06-30 was $39.01M, a 1.91% decline year-over-year.
- Pacific Biosciences of California, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2026-03-31 was $37.18M, a 0.07% increase year-over-year.
- Pacific Biosciences of California, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2025-12-31 was $44.65M, a 13.82% increase year-over-year.
- Pacific Biosciences of California, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2025-09-30 was $38.44M, a 3.82% decline year-over-year.
- Pacific Biosciences of California, Inc. revenue from contract with customer, including assessed tax for fiscal 2025 was $160.00M, a 3.89% increase from fiscal 2024.
- Pacific Biosciences of California, Inc. revenue from contract with customer, including assessed tax for fiscal 2024 was $154.01M, a 23.19% decline from fiscal 2023.
- Pacific Biosciences of California, Inc. revenue from contract with customer, including assessed tax for fiscal 2023 was $200.52M, a 56.29% increase from fiscal 2022.
- Pacific Biosciences of California, Inc. revenue from contract with customer, including assessed tax for fiscal 2022 was $128.30M, a 1.69% decline from fiscal 2021.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $39.01M 10-Q · filed 2026-08-06 | $76.19M 10-Q · filed 2026-08-06 | $120.83M derived: sum of 3 quarters · filed 2026-08-06 | $159.27M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $37.18M 10-Q · filed 2026-05-08 | $81.82M derived: sum of 2 quarters · filed 2026-05-08 | $120.26M derived: sum of 3 quarters · filed 2026-05-08 | $160.03M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $44.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $83.09M derived: sum of 2 quarters · filed 2026-02-25 | $122.85M derived: sum of 3 quarters · filed 2026-08-06 | $160.00M 10-K · filed 2026-02-25 |
| 2025-09-30 | $38.44M 10-Q · filed 2025-11-06 | $78.21M derived: sum of 2 quarters · filed 2026-08-06 | $115.36M 10-Q · filed 2025-11-06 | $154.58M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $39.77M 10-Q · filed 2026-08-06 | $76.92M 10-Q · filed 2026-08-06 | $116.14M derived: sum of 3 quarters · filed 2026-08-06 | $156.11M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $37.15M 10-Q · filed 2026-05-08 | $76.38M derived: sum of 2 quarters · filed 2026-05-08 | $116.34M derived: sum of 3 quarters · filed 2026-05-08 | $152.36M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $39.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $79.19M derived: sum of 2 quarters · filed 2026-02-25 | $115.20M derived: sum of 3 quarters · filed 2026-02-25 | $154.01M 10-K · filed 2026-02-25 |
| 2024-09-30 | $39.97M 10-Q · filed 2025-11-06 | $75.98M derived: sum of 2 quarters · filed 2025-11-06 | $114.79M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $36.01M 10-Q · filed 2025-08-07 | $74.82M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $38.81M 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $200.52M 10-K · filed 2026-02-25 | |||
| 2022-12-31 | $27.35M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $59.66M derived: sum of 2 quarters · filed 2025-03-17 | $95.13M derived: sum of 3 quarters · filed 2025-03-17 | $128.30M 10-K · filed 2025-03-17 |
| 2022-09-30 | $32.31M 10-Q · filed 2022-11-08 | $67.78M derived: sum of 2 quarters · filed 2022-11-08 | $100.95M 10-Q · filed 2022-11-08 | $136.97M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $35.47M 10-Q · filed 2022-08-08 | $68.64M 10-Q · filed 2022-08-08 | $104.66M derived: sum of 3 quarters · filed 2024-02-28 | $139.55M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $33.17M 10-Q · filed 2022-05-06 | $69.19M derived: sum of 2 quarters · filed 2024-02-28 | $104.08M derived: sum of 3 quarters · filed 2024-02-28 | $134.69M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $36.02M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $70.91M derived: sum of 2 quarters · filed 2024-02-28 | $101.52M derived: sum of 3 quarters · filed 2024-02-28 | $130.51M 10-K · filed 2024-02-28 |
| 2021-09-30 | $34.89M 10-Q · filed 2022-11-08 | $65.50M derived: sum of 2 quarters · filed 2022-11-08 | $94.49M 10-Q · filed 2022-11-08 | $121.63M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $30.61M 10-Q · filed 2022-08-08 | $59.61M 10-Q · filed 2022-08-08 | $86.74M derived: sum of 3 quarters · filed 2023-02-28 | $105.83M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $29.00M 10-Q · filed 2022-05-06 | $56.13M derived: sum of 2 quarters · filed 2023-02-28 | $75.22M derived: sum of 3 quarters · filed 2023-02-28 | $92.29M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $27.14M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $46.22M derived: sum of 2 quarters · filed 2023-02-28 | $63.30M derived: sum of 3 quarters · filed 2023-02-28 | $78.89M 10-K · filed 2023-02-28 |
| 2020-09-30 | $19.08M 10-Q · filed 2021-11-05 | $36.16M derived: sum of 2 quarters · filed 2021-11-05 | $51.76M 10-Q · filed 2021-11-05 | $79.69M derived: sum of 4 quarters · filed 2021-11-05 |
| 2020-06-30 | $17.08M 10-Q · filed 2021-08-06 | $32.67M 10-Q · filed 2021-08-06 | $60.60M derived: sum of 3 quarters · filed 2021-08-06 | $82.52M derived: sum of 4 quarters · filed 2021-08-06 |
| 2020-03-31 | $15.60M 10-Q · filed 2021-05-06 | $43.53M derived: sum of 2 quarters · filed 2021-05-06 | $65.44M derived: sum of 3 quarters · filed 2021-05-06 | $90.06M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $27.93M 10-K · filed 2020-02-28 | $49.84M derived: sum of 2 quarters · filed 2020-11-03 | $74.47M derived: sum of 3 quarters · filed 2020-11-03 | $90.89M 10-K · filed 2022-02-28 |
| 2019-09-30 | $21.91M 10-Q · filed 2020-11-03 | $46.54M derived: sum of 2 quarters · filed 2020-11-03 | $62.96M 10-Q · filed 2020-11-03 | $82.49M derived: sum of 4 quarters · filed 2020-11-03 |
| 2019-06-30 | $24.62M 10-Q · filed 2020-08-06 | $41.05M 10-Q · filed 2020-08-06 | $60.57M derived: sum of 3 quarters · filed 2020-08-06 | $78.73M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $16.43M 10-Q · filed 2020-05-08 | $35.95M derived: sum of 2 quarters · filed 2020-05-08 | $54.11M derived: sum of 3 quarters · filed 2020-05-08 | $75.69M derived: sum of 4 quarters · filed 2020-05-08 |
| 2018-12-31 | $19.53M 10-K · filed 2020-02-28 | $37.69M derived: sum of 2 quarters · filed 2020-02-28 | $59.26M derived: sum of 3 quarters · filed 2020-02-28 | $78.63M 10-K · filed 2021-02-26 |
| 2018-09-30 | $18.16M 10-K · filed 2020-02-28 | $39.74M derived: sum of 2 quarters · filed 2020-02-28 | $59.10M 10-Q · filed 2019-11-07 | $84.03M derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-06-30 | $21.58M 10-K · filed 2020-02-28 | $40.94M 10-Q · filed 2019-08-06 | $65.88M derived: sum of 3 quarters · filed 2020-02-28 | $89.42M derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-03-31 | $19.36M 10-K · filed 2020-02-28 | $44.30M derived: sum of 2 quarters · filed 2020-02-28 | $67.84M derived: sum of 3 quarters · filed 2020-02-28 | $87.92M derived: sum of 4 quarters · filed 2020-02-28 |
| 2017-12-31 | $24.93M 10-K · filed 2019-02-26 | $48.48M derived: sum of 2 quarters · filed 2019-02-26 | $68.55M derived: sum of 3 quarters · filed 2019-02-26 | $93.47M 10-K · filed 2020-02-28 |
| 2017-09-30 | $23.55M 10-K · filed 2019-02-26 | $43.62M derived: sum of 2 quarters · filed 2019-02-26 | $68.53M 10-Q · filed 2018-11-05 | |
| 2017-06-30 | $20.07M 10-K · filed 2019-02-26 | $44.99M 10-Q · filed 2018-08-03 | ||
| 2017-03-31 | $24.91M 10-K · filed 2019-02-26 | |||
| 2016-12-31 | $90.71M 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |